Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema

Pharmacogenetics and Genomics

Volumn 23, Issue 9, 2013, Pages 470-478

  Pare, Guillaume ^a,b   Kubo, Michiaki ^h   Byrd, James B ^c   McCarty, Catherine A ^d   Woodard Grice, Alencia ^e   Teo, Koon K ^a   Anand, Sonia S ^b   Zuvich, Rebecca L ^f   Bradford, Yuki ^f   Ross, Stephanie ^a   Nakamura, Yusuke ⁱ   Ritchie, Marylyn ^g   Brown, Nancy J ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g PENNSYLVANIA STATE UNIVERSITY   (United States)

^h RIKEN YOKOHAMA INSTITUTE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

adverse drug event; angioedema; angiotensin converting enzyme; neprilysin

Indexed keywords

BRADYKININ; MEMBRANE METALLOENDOPEPTIDASE; RAMIPRIL; SUBSTANCE P; TELMISARTAN;

ADULT; AFRICAN AMERICAN; ALLELE; ANALYSIS; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENE; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84882285418     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328363c137     Document Type: Article

References (43)

1. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97:1411-1420.
2. Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009; 151:861-871.
3. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitorassociated angioedema. Immunol Allergy Clin North Am 2006; 26:725-737.
4. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719-2728.
5. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, et al. Clinical profile of angioedema associated with angiotensin convertingenzyme inhibition. JAMA 1988; 260:967-970.
6. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60:8-13.
7. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165:1637-1642.
8. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008; 51:1624-1630.
9. Byrd JB, Woodard-Grice A, Stone E, Lucisano A, Schaefer H, Yu C, et al. Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy 2010; 65:1381-1387.
10. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10:499-509.
11. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA 1997; 278:232-233.
12. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359:789-799.
13. Mallal S, Nolan D,Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
14. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8:186-195.
15. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008; 112:2709-2712.
16. Emanueli C, Grady EF, Madeddu P, Figini M, Bunnett NW, Parisi D, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998; 31:1299-1304.
17. Sulpizio AC, Pullen MA, Edwards RM, Brooks DP. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. J Pharmacol Exp Ther 2004; 309:1141-1147.
18. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359:1027-1036.
19. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
20. McCarty CA,Wilke RA, Giampietro PF, Wesbrook SD, Caldwell MD. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Pers Med 2005; 2:49-79.
21. Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitorassociated angioedema. Pharmacogenet Genomics 2010; 20:532-536.
22. Lu B, Figini M, Emanueli C, Geppetti P, Grady EF, Gerard NP, et al. The control of microvascular permeability and blood pressure by neutral endopeptidase. Nat Med 1997; 3:904-907.
23. Kopp UC, Farley DM, Smith LA. Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P. Am J Physiol 1997; 272:R2009-R2016.
24. Blais CJ, Rouleau JL, Brown NJ, Lepage Y, Spence D, Munoz C, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999; 43:293-302.
25. Duan QL, Nikpoor B, Dube MP, Molinaro G, Meijer IA, Dion P, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 2005; 77:617-626.
26. Bouchard L, Faucher G, Tchernof A, Deshaies Y, Lebel S, Hould FS, et al. Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals. Acta Diabetol 2009; 46:13-21.
27. Cui J, Melista E, Chazaro I, Zhang Y, Zhou X, Manolis AJ, et al. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. J Hypertens 2005; 23:55-62.
28. Seneviratne C, Ait-Daoud N, Ma JZ, Chen G, Johnson BA, Li MD. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology 2009; 34:2442-2449.
29. Weidinger S, Gieger C, Rodriguez E, Baurecht H, Mempel M, Klopp N, et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. PLoS Genet 2008; 4:e1000166.
30. Sleiman PM, Flory J, Imielinski M, Bradfield JP, Annaiah K,Willis-Owen SA, et al. Variants of DENND1B associated with asthma in children. N Engl J Med 2010; 362:36-44.
31. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103-111.
32. Baluk P, Thurston G, Murphy TJ, Bunnett NW, McDonald DM. Neurogenic plasma leakage in mouse airways. Br J Pharmacol 1999; 126:522-528.
33. Blais CJ, Marc-Aurele J, Simmons WH, Loute G, Thibault P, Skidgel RA, et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 1999; 20:421-430.
34. Salek-Ardakani S, So T, Halteman BS, Altman A, Croft M. Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase C theta. J Immunol 2004; 173:6440-6447.
35. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 2005; 15:162-174.
36. Boily G, Larose J, Langlois S, Sinnett D. Identification of transcripts modulated by ETV6 expression. Br J Haematol 2007; 136:48-62.
37. Sakurai T, Yamada T, Kihara-Negishi F, Teramoto S, Sato Y, Izawa T, et al. Effects of overexpression of the Ets family transcription factor TEL on cell growth and differentiation of K562 cells. Int J Oncol 2003; 22:1327-1333.
38. Bocsi J, Richter M, Hambsch J, Barten MJ, Dahnert I, Schneider P, et al. Transient Th1/Th2 disbalance indicates postoperative effusions and edema after cardiopulmonary bypass in children. Cytometry A 2006; 69:165-168.
39. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5:703-708.
40. Delgoffe GM, Pollizzi KN,Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011; 12:295-303.
41. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008; 51:141-147.
42. Willheim M, Ebner C, Baier K, Kern W, Schrattbauer K, Thien R, et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J Allergy Clin Immunol 1997; 100:348-355.
43. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitorassociated angioedema. Hypertension 2009; 54:516-523.